Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Monkhorst

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
BMC Medical Genomics|November 10, 2020
Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)Kris G Samsom, Linda J W Bosch, Luuk J Schipper, et al.
Oncoimmunology|October 25, 2019
Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profileRosa De Groot, Marleen M Van Loenen, Aurélie Guislain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLCKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2025
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery ProtocolKarlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 25, 2023
Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnosticsRoelof Koster, Luuk J Schipper, Noor A A Giesbertz, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 2026
Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancerTeodora Radonic, Sepehr Rahmani-Khajouei, Urania Dafni, et al.
JTO Clinical and Research Reports|August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib TreatmentJ W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 1, 2021
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape ProjectStephen P Finn, Alfredo Addeo, Urania Dafni, et al.
The Journal of Molecular Diagnostics : JMD|May 8, 2021
Clinical Validation of Whole Genome Sequencing for Cancer DiagnosticsPaul Roepman, Ewart de Bruijn, Stef van Lieshout, et al.
Frontiers in Oncology|February 11, 2020
Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing ComplexityDaan van den Broek, T Jeroen N Hiltermann, Bonne Biesma, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
BMC Medical Genomics|November 10, 2020
Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)Kris G Samsom, Linda J W Bosch, Luuk J Schipper, et al.
Oncoimmunology|October 25, 2019
Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profileRosa De Groot, Marleen M Van Loenen, Aurélie Guislain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLCKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2025
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery ProtocolKarlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 25, 2023
Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnosticsRoelof Koster, Luuk J Schipper, Noor A A Giesbertz, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 2026
Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancerTeodora Radonic, Sepehr Rahmani-Khajouei, Urania Dafni, et al.
JTO Clinical and Research Reports|August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib TreatmentJ W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 1, 2021
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape ProjectStephen P Finn, Alfredo Addeo, Urania Dafni, et al.
The Journal of Molecular Diagnostics : JMD|May 8, 2021
Clinical Validation of Whole Genome Sequencing for Cancer DiagnosticsPaul Roepman, Ewart de Bruijn, Stef van Lieshout, et al.
Frontiers in Oncology|February 11, 2020
Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing ComplexityDaan van den Broek, T Jeroen N Hiltermann, Bonne Biesma, et al.
Pageof 11